Advertisement

Topics

Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine

08:18 EDT 19 Jun 2018 | HIT Consultants

Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the companies will leverage expertise in genomics and molecular information to enhance the development of perdsonalized medicines and care for patients with cancer. Foundation Medicine, ... Read More

Original Article: Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine

NEXT ARTICLE

More From BioPortfolio on "Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...